ReviewFrontiers in immunology2026
Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) represent the standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, as the disease progresses, targeted resistance inevitably develops. Chemoimmunotherapy, as the standard treatment for advanced NSCLC without driver gene mutations, has significantly improved patient survival. EGFR-mutant tumors exhibit unique immunogenicity compared to wild-type tumors, with heterogeneity in programmed death ligand 1(PD-L1) expression levels, tumor mutational burden (TMB), and other immune microenvironment characteristics. Therefore, we elucidate the mechanisms of immune resistance in EGFR-mutant patients and analyze the core immune mechanisms underlying EGFR-TKI resistance. We summarize the application of immune checkpoint inhibitors (ICIs) in advanced EGFR-mutant NSCLC and analyze the associated mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.